Mednet Logo
HomeHematology
Hematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

Does receiving IVIG confound the result of SPEP and/or UPEP?

4
2 Answers

Mednet Member
Mednet Member
Hematology · John Theurer Cancer Center Hackensack Univ Med Center

IVIG being a product of polyclonal immunoglobulins may ‘produce’ a monoclonal spike if the AUC is falsely calculated by the reader. IFE usually shows polyclonal banding but every now and then a monoclonal band is picked up. Being an IgG molecule with a 21 day halflife; and with the assumption that i...

How would you approach a patient with vitreoretinal lymphoma without CNS or systemic involvement?

1
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Duke University Medical Center

The optimal treatment approach for primary intraocular lymphoma is debated. This is a rare disease with only small retrospective series guiding therapy. There is no clear superior treatment approach in the literature. In clinical practice, younger patients are often treated initially with high-dose ...

Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?

5
2 Answers

Mednet Member
Mednet Member
Infectious Disease · Harbor - UCLA Medical Center

PCV-21 was recently approved by the FDA and supported by ACIP. At this early stage (August 2024), CDC has not finalized guidance on PCV-21, so we do not know how the vaccine schedule will be changed. An important distinction is that PCV-21 covers different serotypes of pneumococcus, as outlined in t...

When would you phlebotomize patients with secondary hemochromatosis, such as due to NAFLD/cirrhosis?

3
1 Answers

Mednet Member
Mednet Member
Hematology · Weill Cornell Medical College and Houston Methodist Hospital

My simple answer is “rarely, if ever” (but it can get much more complicated). Related to hepcidin changes, patients with chronic liver disease frequently have elevated serum ferritin and transferrin saturation, more so with alcoholic liver disease and non-alcoholic fatty liver disease. It is far fro...

How would you treat AML in a pregnant patient at 12 weeks' gestation?

1 Answers

Mednet Member
Mednet Member
Hematology · University of Chicago

My answer is under the assumption that, after a multi-disciplinary discussion with the patient, oncology/leukemia team, and maternal fetal medicine, the objective is to initiate AML-directed therapy while maintaining the pregnancy. The highest risk of deleterious impact to the fetus from chemotherap...

How do you treat factor XI deficient patients with surgery or trauma related bleeding?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · UNMC

Given the risk of elevated plasminogen with low FXI, prefer FFP, with fibrinolytic if mucosal bleeding.

What is your approach to utilizing MRD-guided therapy in previously untreated CLL, particularly in choosing between continuous versus time-limited treatment?

3 Answers

Mednet Member
Mednet Member
Medical Oncology · UPMC Hillman Cancer Center

The question of what to do relative to a patient receiving therapy for CLL in first line and being MRD negative in blood/bone marrow with a reliable test (NGS sequencing or high sensitivity flow cytometry) and also no enlarged lymph nodes on CT/exam greater than 1.5 cm is challenging. For ibrutinib ...

For iron deficiency anemia due to heavy menstrual bleeding, what is your preferred method of controlling heavy menses?

3 Answers

Mednet Member
Mednet Member
Hematology · The Mass General Porphyria Center

I definitely loop in my GYN friends for this one! According to ACOG: "Heavy menstrual bleeding is defined as excessive menstrual blood loss that interferes with a woman's physical, social, emotional, or material quality of life." The consequences of HMB are substantial and multifaceted, and, as we f...

Would you continue or stop anticoagulation for a DVT/PE in a patient with active cancer who has completed 6 months of therapy?

1
3 Answers

Mednet Member
Mednet Member
General Internal Medicine · University of California, San Francisco

This is an important question that we didn’t really have a clear answer for… until this year when an NEJM RCT was published! Mahé et al., PMID 40162636 In this RCT, patients with cancer-associated VTE who completed 6 months of full-dose apixaban were randomized to half-dose apixaban vs. full-dos...

How do you manage erythrocytosis secondary to sotatercept for patients with PAH?

1 Answers

Mednet Member
Mednet Member
Pulmonology · Temple University Hospital

I have not done that yet, but I have let Hgb drift up to 18-19 and monitor the patient closely. I lower the dose to 0.5 or even 0.3, if Hgb is high at baseline, then start and stay at 0.3 before I increase. I will consider phlebotomy if the above options are not available.